Overview

This Solution Provider Webinar is brought to you by DIA in cooperation with PAREXEL International Corporation.

This on demand webinar will take approximately 1 hour to complete

Adaptive Trial Designs have been around for years; however, surprising new research conducted by the Economist Intelligence Unit and commissioned by PAREXEL shows that, while this innovation has a material positive impact on the likelihood of launch of new drugs, it is not widely used. This webinar will explore some of the barriers to adoption of adaptive designs and ways to overcome them, illustrate different types of Adaptive Trial Designs, reference the recent FDA guidance on Adaptive Trial Designs, and present an illuminating case study.

Featured topics

Research findings from The Economist Intelligence Unit and PAREXEL
Recent FDA Draft Guidance on the use of Adaptive Trial Designs and Draft Guidance on Master Protocols
Barriers to adoption by biopharmaceutical companies and solutions to overcome them
Types of Adaptive Trial Designs
A case study of an adaptive trial in schizophrenia with interim analysis and sample size re-estimation

Who should attend?

Professionals who work in the area of:

Learning objectives

At the conclusion of this on-demand webinar, participants should be able to:

Realize the impact Adaptive Trial Designs have on clinical development and new drug launch
Appreciate the different type of Adaptive Trial Designs
Understand the new FDA guidance and how it impacts their organization
Gain insight into obstacles to utilizing Adaptive Trial Designs and ways to overcome them

Continuing Education Credits are not available for this event.

Have an account?

Adaptive Trial Designs: What You Need to Know

Overview

Featured topics

Who should attend?

Learning objectives

Be informed and stay engaged.